Autoimmunity Reviews

Papers
(The H4-Index of Autoimmunity Reviews is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Editorial Board236
The rationale for the use of corticosteroids in early severe Guillain-Barré syndrome174
Editorial Board149
“Fibromyalgia syndrome” related to Essure devices136
Leflunomide: A safe and effective alternative in systemic lupus erythematosus134
Proteomics and enriched biological processes in Antiphospholipid syndrome: A systematic review98
The role of musculoskeletal ultrasound in difficult-to-treat RA: Insights from a systematic literature review90
Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders86
Issues in autoantibody tests used in the classification criteria for autoimmune rheumatic diseases: the laboratory autoimmunologist's perspective86
Editorial Board85
Lymphocyte activation gene-3 (LAG-3) regulatory T cells: An evolving biomarker for treatment response in autoimmune diseases84
Characteristics and risk factors for infection in patients with ANCA-associated vasculitis: A systematic review and meta-analysis80
A critical view on autoantibodies in lupus nephritis: Concrete knowledge based on evidence74
Osteonecrosis in systemic lupus erythematosus: Systematic insight from the epidemiology, pathogenesis, diagnosis and management69
T lymphocyte plasticity in chronic inflammatory diseases: The emerging role of the Ikaros family as a key Th17-Treg switch67
Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis67
Susac syndrome: A scoping review66
Editorial Board61
Conceiving complexity: Biological mechanisms underpinning the lasting effect of pregnancy on multiple sclerosis outcomes61
Endometriosis and autoimmunity61
A call for uniformity in reporting patient level details during description of ophthalmologic major relapse among giant cell arteritis studies. A comment on article by Aussedat M et al. “Epidemiology 61
The immune system in Hashimoto's thyroiditis: Updating the current state of knowledge on potential therapies and animal model construction59
Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature59
Can anticoagulation be withdrawn in APS patients after aPL negativization?57
Human abdominal aortic aneurysm (AAA): Evidence for an autoimmune antigen-driven disease.56
Psychiatric manifestations of autoimmune encephalitis56
To treat or not to treat rheumatoid arthritis with glucocorticoids? A reheated debate55
The impact of the COVID-19 pandemic on autoimmune diagnostics in Europe: A lesson to be learned54
Metabolic heterogeneity in tumor microenvironment – A novel landmark for immunotherapy54
WITHDRAWN: Global incidence trends of autoimmune diseases from 1990 to 2021 and projections to 2050: A systemic analysis of the global burden of disease study 202152
Homocysteine as a trigger and potential therapeutic target for autoimmune diseases51
Inflammatory bowel disease in primary immunodeficiency disorders is a heterogeneous clinical entity requiring an individualized treatment strategy: A systematic review50
Worsening of Graves' ophthalmopathy after SARS-CoV-2 mRNA vaccination49
Infectious agents breaking the immunological tolerance: The holy grail in rheumatoid arthritis reconsidered48
Seronegative autoimmune diseases: A challenging diagnosis47
Autoimmunity in vitiligo: Therapeutic implications and opportunities45
Fecal microbiota transplantation in autoimmune diseases – An extensive paper on a pathogenetic therapy44
Autoimmune pre-disease43
Rebalancing redox homeostasis: A pivotal regulator of the cGAS-STING pathway in autoimmune diseases42
Indian Rheumatology Association guidelines for the management of ANCA associated vasculitis41
Cardiovascular outcome in adult-onset Kawasaki disease41
A descriptive study of IgG4-related disease in children and young adults41
0.095722913742065